Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.32
BRLI's Cash to Debt is ranked higher than
54% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. BRLI: 0.32 )
BRLI' s 10-Year Cash to Debt Range
Min: 0.03   Max: 1.39
Current: 0.32

0.03
1.39
Equity to Asset 0.67
BRLI's Equity to Asset is ranked higher than
76% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. BRLI: 0.67 )
BRLI' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.73
Current: 0.67

0.34
0.73
F-Score: 3
Z-Score: 5.86
M-Score: -1.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.02
BRLI's Operating margin (%) is ranked higher than
85% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. BRLI: 10.02 )
BRLI' s 10-Year Operating margin (%) Range
Min: -6.49   Max: 12.39
Current: 10.02

-6.49
12.39
Net-margin (%) 5.62
BRLI's Net-margin (%) is ranked higher than
82% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. BRLI: 5.62 )
BRLI' s 10-Year Net-margin (%) Range
Min: -9.28   Max: 8.27
Current: 5.62

-9.28
8.27
ROE (%) 16.11
BRLI's ROE (%) is ranked higher than
91% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. BRLI: 16.11 )
BRLI' s 10-Year ROE (%) Range
Min: -35.97   Max: 24.15
Current: 16.11

-35.97
24.15
ROA (%) 10.41
BRLI's ROA (%) is ranked higher than
92% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. BRLI: 10.41 )
BRLI' s 10-Year ROA (%) Range
Min: -13.68   Max: 14.14
Current: 10.41

-13.68
14.14
ROC (Joel Greenblatt) (%) 34.44
BRLI's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. BRLI: 34.44 )
BRLI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -19.55   Max: 43.5
Current: 34.44

-19.55
43.5
Revenue Growth (3Y)(%) 14.70
BRLI's Revenue Growth (3Y)(%) is ranked higher than
93% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. BRLI: 14.70 )
BRLI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 1.3   Max: 22.4
Current: 14.7

1.3
22.4
EBITDA Growth (3Y)(%) 1.10
BRLI's EBITDA Growth (3Y)(%) is ranked higher than
75% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. BRLI: 1.10 )
BRLI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -18.1   Max: 37.3
Current: 1.1

-18.1
37.3
EPS Growth (3Y)(%) 9.20
BRLI's EPS Growth (3Y)(%) is ranked higher than
82% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. BRLI: 9.20 )
BRLI' s 10-Year EPS Growth (3Y)(%) Range
Min: -61.8   Max: 196.2
Current: 9.2

-61.8
196.2
» BRLI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BRLI Guru Trades in Q4 2013

Paul Tudor Jones 31,198 sh (+65.07%)
Mario Gabelli 56,400 sh (+1.26%)
Chuck Royce 115,600 sh (unchged)
Chase Coleman 720,000 sh (unchged)
Jean-Marie Eveillard 12,000 sh (unchged)
Joel Greenblatt 30,507 sh (-35.54%)
» More
Q1 2014

BRLI Guru Trades in Q1 2014

Manning & Napier Advisors, Inc 447,026 sh (New)
Steven Cohen 21,122 sh (New)
Chuck Royce 258,934 sh (+123.99%)
Mario Gabelli 58,700 sh (+4.08%)
Jean-Marie Eveillard 12,000 sh (unchged)
Chase Coleman 720,000 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones 15,400 sh (-50.64%)
» More
Q2 2014

BRLI Guru Trades in Q2 2014

John Hussman 50,000 sh (New)
Paul Tudor Jones 19,717 sh (+28.03%)
Chuck Royce 304,334 sh (+17.53%)
Chase Coleman 720,000 sh (unchged)
Steven Cohen 8,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Jean-Marie Eveillard Sold Out
Mario Gabelli 58,500 sh (-0.34%)
» More
Q3 2014

BRLI Guru Trades in Q3 2014

John Hussman 59,000 sh (+18%)
Paul Tudor Jones 21,700 sh (+10.06%)
Chase Coleman 720,000 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 58,000 sh (-0.85%)
Chuck Royce 280,900 sh (-7.7%)
» More
» Details

Insider Trades

Latest Guru Trades with BRLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-06-30 New Buy0.12%$24.74 - $32.74 $ 29.918%50000
Jean-Marie Eveillard 2014-06-30 Sold Out $24.74 - $32.74 $ 29.918%0
Joel Greenblatt 2014-03-31 Sold Out 0.02%$24.39 - $28.26 $ 29.9114%0
Joel Greenblatt 2013-12-31 Reduce -35.54%0.02%$25.17 - $37.73 $ 29.91-3%30507
John Hussman 2013-09-30 Sold Out 0.15%$25.78 - $30.14 $ 29.918%0
Joel Greenblatt 2013-06-30 Reduce -46.02%0.06%$23.58 - $31.9 $ 29.919%56271
John Hussman 2013-03-31 New Buy0.11%$24.91 - $31.05 $ 29.918%116000
Joel Greenblatt 2013-03-31 Add 21.81%0.03%$24.91 - $31.05 $ 29.918%104240
Joel Greenblatt 2012-12-31 Add 48.67%0.05%$24.68 - $32.42 $ 29.914%85579
Joel Greenblatt 2012-03-31 New Buy0.12%$16.27 - $23.76 $ 29.9159%57406
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Bio-Reference Laboratories Inc

Medical Diagnostic Labs Facing Medicare Headwinds
Currently medical diagnostic lab stocks are trading at near historical lows for price-to-sales (P/S). At first sight these companies might look like bargains, but lower p/s ratios might be the new normal for these companies. I have taken a closer look at Lab Corp of America (LH), Quest Diagnostics (DGX), and Bio-Reference Labs (BRLI). Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 17.70
BRLI's P/E(ttm) is ranked higher than
96% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRLI: 17.70 )
BRLI' s 10-Year P/E(ttm) Range
Min: 9.34   Max: 39.85
Current: 17.7

9.34
39.85
P/B 2.60
BRLI's P/B is ranked higher than
82% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. BRLI: 2.60 )
BRLI' s 10-Year P/B Range
Min: 1.77   Max: 7.83
Current: 2.6

1.77
7.83
P/S 1.00
BRLI's P/S is ranked higher than
94% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.17 vs. BRLI: 1.00 )
BRLI' s 10-Year P/S Range
Min: 0.61   Max: 2.44
Current: 1

0.61
2.44
EV-to-EBIT 10.40
BRLI's EV-to-EBIT is ranked higher than
96% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRLI: 10.40 )
BRLI' s 10-Year EV-to-EBIT Range
Min: 5.9   Max: 28.6
Current: 10.4

5.9
28.6
PEG 1.88
BRLI's PEG is ranked higher than
95% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRLI: 1.88 )
BRLI' s 10-Year PEG Range
Min: 0.36   Max: 1.57
Current: 1.88

0.36
1.57
Shiller P/E 22.05
BRLI's Shiller P/E is ranked higher than
95% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRLI: 22.05 )
BRLI' s 10-Year Shiller P/E Range
Min: 15.23   Max: 270
Current: 22.05

15.23
270
Current Ratio 2.69
BRLI's Current Ratio is ranked higher than
73% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. BRLI: 2.69 )
BRLI' s 10-Year Current Ratio Range
Min: 1.12   Max: 3.11
Current: 2.69

1.12
3.11
Quick Ratio 2.69
BRLI's Quick Ratio is ranked higher than
77% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. BRLI: 2.69 )
BRLI' s 10-Year Quick Ratio Range
Min: 1.09   Max: 2.9
Current: 2.69

1.09
2.9

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 15.03
BRLI's Price/Net Current Asset Value is ranked higher than
83% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRLI: 15.03 )
BRLI' s 10-Year Price/Net Current Asset Value Range
Min: 12.39   Max: 50.13
Current: 15.03

12.39
50.13
Price/Tangible Book 3.08
BRLI's Price/Tangible Book is ranked higher than
86% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.25 vs. BRLI: 3.08 )
BRLI' s 10-Year Price/Tangible Book Range
Min: 0.92   Max: 8.73
Current: 3.08

0.92
8.73
Price/DCF (Projected) 2.12
BRLI's Price/DCF (Projected) is ranked higher than
87% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRLI: 2.12 )
BRLI' s 10-Year Price/DCF (Projected) Range
Min: 2.13   Max: 6.69
Current: 2.12

2.13
6.69
Price/Median PS Value 0.78
BRLI's Price/Median PS Value is ranked higher than
93% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. BRLI: 0.78 )
BRLI' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 1.51
Current: 0.78

0.12
1.51
Price/Peter Lynch Fair Value 1.48
BRLI's Price/Peter Lynch Fair Value is ranked higher than
96% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRLI: 1.48 )
BRLI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.62   Max: 1.49
Current: 1.48

0.62
1.49
Price/Graham Number 1.55
BRLI's Price/Graham Number is ranked higher than
95% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRLI: 1.55 )
BRLI' s 10-Year Price/Graham Number Range
Min: 0.51   Max: 5.26
Current: 1.55

0.51
5.26
Earnings Yield (Greenblatt) 9.60
BRLI's Earnings Yield (Greenblatt) is ranked higher than
96% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. BRLI: 9.60 )
BRLI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.5   Max: 17
Current: 9.6

3.5
17
Forward Rate of Return (Yacktman) 12.87
BRLI's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.28 vs. BRLI: 12.87 )
BRLI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.8   Max: 34.9
Current: 12.87

0.8
34.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX » details
Traded in other countries:BFR.Germany,
Bio-Reference Laboratories Inc is a New Jersey corporation incorporated on December 24, 1981. It offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. It also offers laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. The Company is engaged in esoteric testing, molecular diagnostics, anatomical pathology, genetics, womens health and correctional health care. The Company has a network of approximately 116 patient service centers located in the Northeast (in New York metropolitan super-regional area) for collection of patient specimens. It conducts business in New York State counties, as well as in New Jersey, Maryland, Pennsylvania, Delaware and Connecticut. It offers laboratory services to physician offices in these areas with an infrastructure that includes a comprehensive logistical department, phlebotomy services and phlebotomy draw stations. The Company operates a clinical knowledge management service through its PSIMedica business unit. The system uses customer data from laboratory results, pharmaceutical data, claims data and other data sources provide administrative and clinical decision support systems that enable customers to provide quality and efficient healthcare to their populations. It also operates a web-based connectivity portal solution for laboratories and physicians through its CareEvolve subsidiary. The Company competes with three types of providers in a highly fragmented and competitive industry: hospital laboratories, physician-office laboratories and other independent clinical laboratories. Its competitors in the New York metropolitan area are Quest Diagnostics (DGX) and Laboratory Corporation of America (LH). The Company is subject to federal and state laws and regulations regarding the protection of the environment, the health and safety of employees, and the handling, transportation and disposal of medical specimens, and infectious and hazardous wastes.
» More Articles for BRLI

Headlines

Articles On GuruFocus.com
Small cap high short interest (Predictability = 5), Part 1 Oct 16 2014 
Why I Like These Two Health Care Stocks Aug 29 2014 
LabCorp: A Leading Independent Diagnostic Laboratory Aug 22 2014 
DaVita Seems to be a High-Growth Company Aug 20 2014 
Small-Cap Consensus Picks By The Investing Gurus Jul 25 2014 
4 Attractive Small-Cap Growth + Value Stocks You Have Never Heard Of Apr 16 2014 
Medical Diagnostic Labs Facing Medicare Headwinds Mar 25 2014 
Historical Short Interest Of Stocks – New Feature Announcement Jan 17 2014 
New Feature Announcement: Stocks With The Highest Short Interest Dec 12 2013 
comment on BRLI May 11 2013 

More From Other Websites
Bio-Reference Laboratories Inc Earnings Call scheduled for 10:30 am ET today Dec 18 2014
BioReference Laboratories, Inc. Announces Quarterly and Yearly Record Revenues, Net Income and... Dec 18 2014
Bio-Reference Laboratories posts 4Q profit Dec 18 2014
Bio-Reference Laboratories posts 4Q profit Dec 18 2014
BIO REFERENCE LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Dec 18 2014
BioReference Laboratories, Inc. Announces Quarterly and Yearly Record Revenues, Net Income and... Dec 18 2014
Q4 2014 Bio-Reference Laboratories Inc Earnings Release - Before Market Open Dec 18 2014
BioReference Laboratories, Inc. Announces Earnings Date for Fourth Quarter and Year End for Fiscal... Dec 11 2014
BioReference Laboratories, Inc. Announces Earnings Date for Fourth Quarter and Year End for Fiscal... Dec 11 2014
Genomics startup NextCode stakes claim in pediatric disease market Dec 10 2014
Bear of the Day: Invacare Corp (IVC) Nov 24 2014
BIO REFERENCE LABORATORIES INC Financials Sep 10 2014
BIO REFERENCE LABORATORIES INC Files SEC form 10-Q, Quarterly Report Sep 04 2014
Bio-Reference Laboratories (BRLI) Crumbles: Stock Tumbles by 9.2% Aug 29 2014
Bio-Reference Laboratories Inc Earnings Call scheduled for 10:30 am ET today Aug 27 2014
BIO REFERENCE LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 27 2014
Lessons To Take From Health Care's Strong 2014 And What To Buy Now Aug 25 2014
Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference... Aug 18 2014
Myriad Genetics Guidance Disappoints, Q4 Edges Views Aug 12 2014
Myriad Genetics' Earnings Face 'Angelina Jolie' Comps Aug 11 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK